Editorial
George C. Prendergast
Cancer Res January 1 2010 70 (1) 1-3; DOI:10.1158/0008-5472.CAN-09-4246
Table of Contents
Editorial
Reviews
- ReviewsKristy A. Brown and Evan R. SimpsonCancer Res January 1 2010 70 (1) 4-7; DOI:10.1158/0008-5472.CAN-09-2257
AMP kinase, a master regulator of cellular energy metabolism, may provide a key link between obesity-associated inflammation and increased breast cancer risk.
- ReviewsMara Gallí, Frédéric Van Gool, Anthony Rongvaux, Fabienne Andris and Oberdan LeoCancer Res January 1 2010 70 (1) 8-11; DOI:10.1158/0008-5472.CAN-09-2465
NAMPT has properties of a positive biological modifier of NAD-dependent inflammation and cell growth that prompt interest in it as a pharmacological target for cancer treatment.
Meeting Reports
- Meeting ReportsOlaf Wolkenhauer, Charles Auffray, Simone Baltrusch, Nils Blüthgen, Helen Byrne, Marta Cascante, Andrea Ciliberto, Trevor Dale, Dirk Drasdo, David Fell, James E. Ferrell Jr., Daniel Gallahan, Robert Gatenby, Ulrich Günther, Brian D. Harms, Hanspeter Herzel, Christian Junghanss, Manfred Kunz, Ingeborg van Leeuwen, Philippe Lenormand, Francis Levi, Michael Linnebacher, John Lowengrub, Philip K. Maini, Arif Malik, Katja Rateitschak, Owen Sansom, Reinhold Schäfer, Karsten Schürrle, Christine Sers, Santiago Schnell, Darryl Shibata, John Tyson, Julio Vera, Michael White, Boris Zhivotovsky and Robert JasterCancer Res January 1 2010 70 (1) 12-13; DOI:10.1158/0008-5472.CAN-09-2676
This meeting report summarizes discussions among systems biologists concerning how to achieve greater integration of approaches in the field with the mainstream of cancer research.
- Meeting ReportsEnrico Mihich, Pier Paolo Pandolfi and David LivingstonCancer Res January 1 2010 70 (1) 14-17; DOI:10.1158/0008-5472.CAN-09-3368
Priority Reports
- Priority ReportsVu H. Nguyen, Hyung-Seok Kim, Jung-Min Ha, Yeongjin Hong, Hyon E. Choy and Jung-Joon MinCancer Res January 1 2010 70 (1) 18-23; DOI:10.1158/0008-5472.CAN-09-3453
Study describes a creative new biological approach to image and treat metastatic disease.
- Priority ReportsMayuko Y. Kumasaka, Ichiro Yajima, Khaled Hossain, Machiko Iida, Toyonori Tsuzuki, Tamio Ohno, Masahide Takahashi, Masashi Yanagisawa and Masashi KatoCancer Res January 1 2010 70 (1) 24-29; DOI:10.1158/0008-5472.CAN-09-2838
Decreased Endothelin receptor B signals facilitate de novo melanomas that do not arise from nevi.
- Priority ReportsSeth R. Ogden, Jennifer M. Noto, Shannon S. Allen, Dilan A. Patel, Judith Romero-Gallo, M. Kay Washington, Barbara Fingleton, Dawn A. Israel, Nuruddeen D. Lewis, Keith T. Wilson, Rupesh Chaturvedi, Zhiguo Zhao, Yu Shyr and Richard M. Peek Jr.Cancer Res January 1 2010 70 (1) 30-35; DOI:10.1158/0008-5472.CAN-09-2899
Eradication of H. pylori infections in stomach has been associated with an increased incidence of upper GI cancers, perhaps as a result of a greater incidence of gastric inflammation normally reduced by an H. pylori-induced extracellular protease.
Clinical Studies
- Clinical StudiesSantosh K. Patnaik, Eric Kannisto, Steen Knudsen and Sai YendamuriCancer Res January 1 2010 70 (1) 36-45; DOI:10.1158/0008-5472.CAN-09-3153
Improving the ability to predict relapse of localized lung adenocarcinoma after surgical resection, through the miRNA expression profiling methods reported in this study, may alter therapeutic decisions and improve patient outcomes.
Integrated Systems and Technologies
- Integrated Systems and TechnologiesAndrea Sottoriva, Joost J.C. Verhoeff, Tijana Borovski, Shannon K. McWeeney, Lev Naumov, Jan Paul Medema, Peter M.A. Sloot and Louis VermeulenCancer Res January 1 2010 70 (1) 46-56; DOI:10.1158/0008-5472.CAN-09-3663
Therapies that are less effective against cancer stem cells may quicken tumor evolution, increasing tumor heterogeneity and speeding the development of tumor progression and drug resistance.
Microenvironment and Immunology
- Microenvironment and ImmunologyYingjie Wu, Pnina Brodt, Hui Sun, Wilson Mejia, Ruslan Novosyadlyy, Nomeli Nunez, Xiaoli Chen, Arnulfo Mendoza, Sung-Hyeok Hong, Chand Khanna and Shoshana YakarCancer Res January 1 2010 70 (1) 57-67; DOI:10.1158/0008-5472.CAN-09-2472
To facilitate liver metastasis, IGF-1 must act beyond the tumor cell to provide an essential support to obesity-associated inflammatory processes in the tumor microenvironment.
- Microenvironment and ImmunologyMinu K. Srivastava, Pratima Sinha, Virginia K. Clements, Paulo Rodriguez and Suzanne Ostrand-RosenbergCancer Res January 1 2010 70 (1) 68-77; DOI:10.1158/0008-5472.CAN-09-2587
MDSC promote tumor formation by suppressing T cell activity through multiple mechanisms, including by blocking their essential need for cysteine.
- Microenvironment and ImmunologyMichael T. Spiotto, Alice Banh, Ioanna Papandreou, Hongbin Cao, Michael G. Galvez, Geoffrey C. Gurtner, Nicholas C. Denko, Quynh Thu Le and Albert C. KoongCancer Res January 1 2010 70 (1) 78-88; DOI:10.1158/0008-5472.CAN-09-2747
Imaging a central marker of the unfolded protein response identifies regions of tumor growth.
- Microenvironment and ImmunologyZhuohan Zhang, Qiaofei Liu, Yongzhe Che, Xin Yuan, Lingyun Dai, Bin Zeng, Guohui Jiao, Yin Zhang, Xue Wu, Yinyan Yu, Yuan Zhang and Rongcun YangCancer Res January 1 2010 70 (1) 89-98; DOI:10.1158/0008-5472.CAN-09-2970
Metabolic aberrations in tumors affect not only tumor cells but other cell types in the tumor, including immune cells whose antigen presenting capacity becomes subverted.
- Microenvironment and ImmunologyPing-Ying Pan, Ge Ma, Kaare J. Weber, Junko Ozao-Choy, George Wang, Bingjiao Yin, Celia M. Divino and Shu-Hsia ChenCancer Res January 1 2010 70 (1) 99-108; DOI:10.1158/0008-5472.CAN-09-1882
Findings define a tractable approach to degrade two important cellular mechanisms of immune suppression that are erected by advanced tumors and that inhibit the efficacy of immune stimulatory therapies.
- Microenvironment and ImmunologyZvi G. Fridlender, George Buchlis, Veena Kapoor, Guanjun Cheng, Jing Sun, Sunil Singhal, M. Cecilia Crisanti, Liang-Chuan S. Wang, Daniel Heitjan, Linda A. Snyder and Steven M. AlbeldaCancer Res January 1 2010 70 (1) 109-118; DOI:10.1158/0008-5472.CAN-09-2326
Chemokine attack may offer an effective way to degrade immune escape by tumors, heightening the antitumor response to vaccines.
- Microenvironment and ImmunologyJennifer B. Jacob, Elena Quaglino, Olga Radkevich-Brown, Richard F. Jones, Marie P. Piechocki, Joyce D. Reyes, Amy Weise, Augusto Amici and Wei-Zen WeiCancer Res January 1 2010 70 (1) 119-128; DOI:10.1158/0008-5472.CAN-09-2554
A straightforward tactic to increase the effective immunogenicity of anti-cancer DNA vaccines is demonstrated.
- Microenvironment and ImmunologyTao Gu, Rachael B. Rowswell-Turner, Mehmet O. Kilinc and Nejat K. EgilmezCancer Res January 1 2010 70 (1) 129-138; DOI:10.1158/0008-5472.CAN-09-3170
IFNγ, which is critical to the antitumor activity of IL-12, is also responsible for inducing the feedback inhibitory mechanisms that regulate post-IL-12 immune responses. Specifically, IFNg induces the enzyme indoleamine 2,3 dioxygenase (IDO), which in turn promotes the expansion of CD4+ CD25+ Foxp3+ T-suppressor cells, short-circuiting post-therapy antitumor T-effector activity.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyHazel C. Thoms, Carolyn J. Loveridge, James Simpson, Alexandra Clipson, Karina Reinhardt, Malcolm G. Dunlop and Lesley A. StarkCancer Res January 1 2010 70 (1) 139-149; DOI:10.1158/0008-5472.CAN-09-1397
Findings define a subnuclear targeting mechanism by which the function of the NF-κB factor RelA can be switched to promote either apoptosis or survival, addressing long-standing questions about this dual nature of NF-κB in different settings, including different cancers.
- Molecular and Cellular PathobiologySebastian Bauer, Joshua A. Parry, Thomas Mühlenberg, Matthew F. Brown, Danushka Seneviratne, Payel Chatterjee, Anna Chin, Brian P. Rubin, Shih-Fan Kuan, Jonathan A. Fletcher, Stefan Duensing and Anette DuensingCancer Res January 1 2010 70 (1) 150-159; DOI:10.1158/0008-5472.CAN-09-1449
Results rationalize the clinical evaluation of bortezimib (Velcade) to treat imatinib-resistant GIST tumors.
- Molecular and Cellular PathobiologyIvan Pasic, Adam Shlien, Adam D. Durbin, Dimitrios J. Stavropoulos, Berivan Baskin, Peter N. Ray, Ana Novokmet and David MalkinCancer Res January 1 2010 70 (1) 160-171; DOI:10.1158/0008-5472.CAN-09-1902
A chromosomal region commonly deleted in osteosarcoma contains a novel group of cooperatively acting tumor suppressors, possibly with significance in other tumors as well.
- Molecular and Cellular PathobiologyAlexei Vazquez, Lukasz F. Grochola, Elisabeth E. Bond, Arnold J. Levine, Helge Taubert, Thomas H. Müller, Peter Würl and Gareth L. BondCancer Res January 1 2010 70 (1) 172-180; DOI:10.1158/0008-5472.CAN-09-2218
SNPs in 2 of 142 genes in the p53 network may predict clinical responses in chemotherapy of soft tissue sarcomas.
- Molecular and Cellular PathobiologyDavid C. Adamson, Qun Shi, Matthew Wortham, Paul A. Northcott, Chunhui Di, Christopher G. Duncan, Jianjun Li, Roger E. McLendon, Darell D. Bigner, Michael D. Taylor and Hai YanCancer Res January 1 2010 70 (1) 181-191; DOI:10.1158/0008-5472.CAN-09-2331
Findings define the developmental transcription factor OTX2 as a central oncogenic driver in medulloblastoma.
- Molecular and Cellular PathobiologyLi-Fang Lin, Chih-Hung Chuang, Chien-Feng Li, Ching-Chun Liao, Chun-Pei Cheng, Tian-Lu Cheng, Meng-Ru Shen, Joseph T. Tseng, Wen-Chang Chang, Wen-Hwa Lee and Ju-Ming WangCancer Res January 1 2010 70 (1) 192-201; DOI:10.1158/0008-5472.CAN-09-2641
Transcriptional repressor ZBRK1 upregulated by BRCA1 has properties that may offer new insights into metastasis susceptibility in cervical carcinomas.
- Molecular and Cellular PathobiologyHong Gao, Yi Le, Xiaoming Wu, Leslie E. Silberstein, Roger W. Giese and Zhenglun ZhuCancer Res January 1 2010 70 (1) 202-211; DOI:10.1158/0008-5472.CAN-09-2668
Attenuations in the expression of a novel LEF/TCF pathway effector in hemtopoeitic cells might contribute to the development of chronic lymphocytic leukemia (CLL).
- Molecular and Cellular PathobiologyYunxia Fan, Gregory P. Boivin, Erik S. Knudsen, Daniel W. Nebert, Ying Xia and Alvaro PugaCancer Res January 1 2010 70 (1) 212-220; DOI:10.1158/0008-5472.CAN-09-3090
Receptors that are well known to bind and respond to environmental toxins may also exert important unrelated functions in tumor suppression.
- Molecular and Cellular PathobiologyHao Hong, Hai-Yun Yen, Amy Brockmeyer, Ying Liu, Rajas Chodankar, Malcolm C. Pike, Frank Z. Stanczyk, Robert Maxson and Louis DubeauCancer Res January 1 2010 70 (1) 221-228; DOI:10.1158/0008-5472.CAN-09-3232
Groundbreaking findings identify a similar fundamental risk factor underlying sporadic and familial forms of ovarian cancer.
- Molecular and Cellular PathobiologyMaria Paola Paronetto, Manuela Cappellari, Roberta Busà, Simona Pedrotti, Roberta Vitali, Clay Comstock, Terry Hyslop, Karen E. Knudsen and Claudio SetteCancer Res January 1 2010 70 (1) 229-239; DOI:10.1158/0008-5472.CAN-09-2788
Functional alterations in RNA splicing that may occur widely in cancer are known to have significance for certain oncogenes and tumor suppressor genes, but the molecular basis for these alterations is only recently emerging as addressed in this study of cyclin D1 in prostate cancer.
- Molecular and Cellular PathobiologyYuexing Zhang, Tehmina Z. Ali, Hua Zhou, David R. D'Souza, Yan Lu, Jonathan Jaffe, Zhenqiu Liu, Antonino Passaniti and Anne W. HamburgerCancer Res January 1 2010 70 (1) 240-248; DOI:10.1158/0008-5472.CAN-09-2904
Metastatic prostate cancer is sustained by a possible ErbB3 signaling pathway leading through FoxA to the developmental gene AGR2, offering a new realm for therapeutic explorations against this deadly disease.
Prevention and Epidemiology
- Prevention and EpidemiologyMarkus Schmitt, Véronique Dalstein, Tim Waterboer, Christine Clavel, Lutz Gissmann and Michael PawlitaCancer Res January 1 2010 70 (1) 249-256; DOI:10.1158/0008-5472.CAN-09-2514
Molecular diagnostics that could improve primary screening and triage of cervical lesions are described.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyAkinori Morita, Shinichi Yamamoto, Bing Wang, Kaoru Tanaka, Norio Suzuki, Shin Aoki, Azusa Ito, Tomohisa Nanao, Soichiro Ohya, Minako Yoshino, Jin Zhu, Atsushi Enomoto, Yoshihisa Matsumoto, Osamu Funatsu, Yoshio Hosoi and Masahiko IkekitaCancer Res January 1 2010 70 (1) 257-265; DOI:10.1158/0008-5472.CAN-08-3771
Vanadate is commonly employed as an inhibitor of protein tyrosine phosphatases but it is also a potent inhibitor of p53 mediated apoptosis.
- Therapeutics, Targets, and Chemical BiologyNinib Baryawno, Baldur Sveinbjörnsson, Staffan Eksborg, Ching-Shih Chen, Per Kogner and John Inge JohnsenCancer Res January 1 2010 70 (1) 266-276; DOI:10.1158/0008-5472.CAN-09-0578
New strategies to treat a common and deadly pediatric brain tumor are suggested by findings that PI3K/Akt signaling is needed to support β-catenin pathways that are known to mediate tumor cell proliferation and survival.
- Therapeutics, Targets, and Chemical BiologyInge Lindner, Nasr Y.A. Hemdan, Martin Buchold, Klaus Huse, Marina Bigl, Ilka Oerlecke, Albert Ricken, Frank Gaunitz, Ulrich Sack, Andreas Naumann, Margrit Hollborn, Dietmar Thal, Rolf Gebhardt and Gerd BirkenmeierCancer Res January 1 2010 70 (1) 277-287; DOI:10.1158/0008-5472.CAN-09-1462
Study of a negative modifier complex that appears to affect an important signaling pathway in brain tumors may offer a new therapeutic direction.
- Therapeutics, Targets, and Chemical BiologyChristine M. Chresta, Barry R. Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E. Critchlow, John P. Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard Jenkins, Matt Jacobsen, Graeme C.M. Smith, Sylvie Guichard and Martin PassCancer Res January 1 2010 70 (1) 288-298; DOI:10.1158/0008-5472.CAN-09-1751
Small molecule inhibitors of the mTOR complexes represent a recent refinement of strategies to disrupt a fundamental cell growth and survival pathway for the purpose of cancer treatment.
- Therapeutics, Targets, and Chemical BiologyGuanglei Zhuang, Dana M. Brantley-Sieders, David Vaught, Jian Yu, Lu Xie, Sam Wells, Dowdy Jackson, Rebecca Muraoka-Cook, Carlos Arteaga and Jin ChenCancer Res January 1 2010 70 (1) 299-308; DOI:10.1158/0008-5472.CAN-09-1845
Resistance to the HER2 antibody trastuzumab, used widely in breast cancer treatment, may arise partly as a result of its ability to elevate expression of a receptor tyrosine kinase that can promote trastuzumab resistance.
- Therapeutics, Targets, and Chemical BiologyBeatrice Borgia, Christoph Roesli, Tim Fugmann, Christoph Schliemann, Marta Cesca, Dario Neri and Raffaella GiavazziCancer Res January 1 2010 70 (1) 309-318; DOI:10.1158/0008-5472.CAN-09-2939
New prognostic markers predicting metastatic spread of cancers to the liver cancer might be found among 12 vascular proteins identified in a mouse model of liver metastasis.
- Therapeutics, Targets, and Chemical BiologyLiewei Wang, Katarzyna A. Ellsworth, Irene Moon, Linda L. Pelleymounter, Bruce W. Eckloff, Yvette N. Martin, Brooke L. Fridley, Gregory D. Jenkins, Anthony Batzler, Vera J. Suman, Saranya Ravi, J. Michael Dixon, William R. Miller, Eric D. Wieben, Aman Buzdar, Richard M. Weinshilboum and James N. IngleCancer Res January 1 2010 70 (1) 319-328; DOI:10.1158/0008-5472.CAN-09-3224
Personalized therapy with estrogen-lowering drugs may be advanced with findings of pharmacogenomic markers that can predict how efficiently specific patients may respond to treatment.
- Therapeutics, Targets, and Chemical BiologyKim Hei-Man Chow, Raymond Wai-Yin Sun, Janice B.B. Lam, Carrie Ka-Lei Li, Aimin Xu, Dik-Lung Ma, Ruben Abagyan, Yu Wang and Chi-Ming CheCancer Res January 1 2010 70 (1) 329-337; DOI:10.1158/0008-5472.CAN-09-3324
Novel gold compounds with cytotoxic activity based may act by altering an important class of chromatin regulators.
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyVera Levina, Adele Marrangoni, Tingting Wang, Simul Parikh, Yunyun Su, Ronald Herberman, Anna Lokshin and Elieser GorelikCancer Res January 1 2010 70 (1) 338-346; DOI:10.1158/0008-5472.CAN-09-1102
The reliance of lung cancer stem cells on c-Kit signaling suggests a possible opportunity to reposition imatinib (Gleevec) as an adjuvant to cytotoxic chemotherapy for improving lung cancer treatment.
- Tumor and Stem Cell BiologyStephanie L. Swift, Julie E. Burns and Norman J. MaitlandCancer Res January 1 2010 70 (1) 347-356; DOI:10.1158/0008-5472.CAN-09-1252
A class of cell surface receptors upregulated with the acquisition of androgen independence in prostate cancer may be useful as targeting tools.
- Tumor and Stem Cell BiologyAnne-Theres Henze, Johanna Riedel, Tanja Diem, Julia Wenner, Ingo Flamme, Jacques Pouyseggur, Karl H. Plate and Till AckerCancer Res January 1 2010 70 (1) 357-366; DOI:10.1158/0008-5472.CAN-09-1876
Findings suggest novel targets in the HIF pathway of hypoxia response that may sensitize glioblastomas to therapeutic attack.
- Tumor and Stem Cell BiologyStephen S. Myatt, Jun Wang, Lara J. Monteiro, Mark Christian, Ka-Kei Ho, Luca Fusi, Roberto E. Dina, Jan J. Brosens, Sadaf Ghaem-Maghami and Eric W-F. LamCancer Res January 1 2010 70 (1) 367-377; DOI:10.1158/0008-5472.CAN-09-1891
FOXO1 targeting by microRNAs may mediate an important step in endometrial tumorigenesis, suggesting new tactics to restore FOXO1 expression and attack established tumors.
- Tumor and Stem Cell BiologyMohit Sachdeva and Yin-Yuan MoCancer Res January 1 2010 70 (1) 378-387; DOI:10.1158/0008-5472.CAN-09-2021
Study findings confirm the importance of mucins in metastasis and offer proof of concept for use of miR-145 as a novel anti-metastatic therapy.
- Tumor and Stem Cell BiologyMatthew A. Held, David P. Curley, David Dankort, Martin McMahon, Viswanathan Muthusamy and Marcus W. BosenbergCancer Res January 1 2010 70 (1) 388-397; DOI:10.1158/0008-5472.CAN-09-2153
Cancer stem cell theory postulates that more effective therapies will emerge only with better characterization of tumor-propagating cells that may be relatively rare in tumors, yet vital to their growth and evolution, as studied here in new models of melanoma.
- Tumor and Stem Cell BiologyNicole Schatz, Stephanie Brändlein, Kilian Rückl, Frank Hensel and H. Peter VollmersCancer Res January 1 2010 70 (1) 398-408; DOI:10.1158/0008-5472.CAN-09-2186
The capability to directly clone patient antibodies through human hybridoma technology offers a strategy to identify novel 'theranostic' markers in cancer that occur naturally during human tumorigenesis.
- Tumor and Stem Cell BiologyGregory C. Stachelek, Shibani Dalal, Katherine A. Donigan, Denise Campisi Hegan, Joann B. Sweasy and Peter M. GlazerCancer Res January 1 2010 70 (1) 409-417; DOI:10.1158/0008-5472.CAN-09-1353
Findings rationalize an evaluation of patients whose tumors harbor mutations in BRCA2 for treatment with a combination of temozolomide and inhibitors of DNA polymerase β.
- Tumor and Stem Cell BiologySrinivasulu Chigurupati, Rajarajeswari Venkataraman, Daniel Barrera, Anusha Naganathan, Meenu Madan, Leena Paul, Jogi V. Pattisapu, George A. Kyriazis, Kiminobu Sugaya, Sergey Bushnev, Justin D. Lathia, Jeremy N. Rich and Sic L. ChanCancer Res January 1 2010 70 (1) 418-427; DOI:10.1158/0008-5472.CAN-09-2654
A tractable target for drug development acting downstream of Notch may yield new treatments for deadly glioblastomas.
Obituary
- ObituaryBruce A. ChabnerCancer Res January 1 2010 70 (1) 428-429; DOI:10.1158/0008-5472.CAN-09-4146
January 2010
Volume 70, Issue 1
Volume 70, Issue 1
Issue Highlights
Jump to
Advertisement
